Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis
复制标题
DOI：
10.1097/qai.0b013e31815acab8
复制
发表时间：
2008-01-01
影响因子：
3.6
通讯作者：
Cheng, Andrew K.
中科院分区：
文献类型：
--
作者：
Arribas, Jose R.;Pozniak, Anton L.;Cheng, Andrew K.
背景：随着治疗 HIV 感染的抗逆转录病毒疗法的改进，提供长期随访数据的试验变得越来越重要。 方法：与固定剂量齐多夫定/拉米夫定 (ZDV/3TC) 和固定剂量的齐多夫定/拉米夫定 (ZDV/3TC) 方案相比，富马酸替诺福韦二吡呋酯 (TDF)、恩曲他滨 (FTC) 和依非韦伦 (EFV) 方案表现出更好的病毒学、免疫学和形态学效果。在一项随机开放标签试验中，EFV 持续 96 周。 96 周后，接受 TDF + FTC 治疗的患者转为固定剂量组合 TDF/FTC。结果：在 144 周内，TDF/FTC 组中有更多患者达到并维持 HIV RNA 水平
Background: As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important.Methods: A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC.Results: Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level